Lixte Biotech's Losses Mount Amidst Strategic Shift & Nasdaq Scrutiny

TL;DR

**LIXT is burning cash with no revenue, relying on dilutive financing to stay afloat, making it a highly speculative bet on LB-100's distant success.**

AI Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported a net loss of $3,465,626 for the nine months ended September 30, 2025, an increase from a net loss of $2,968,271 in the prior year period. The company generated no revenue in either period. Research and development costs significantly decreased to $202,801 for the nine months ended September 30, 2025, down from $691,402 in the same period of 2024, while general and administrative costs rose to $3,080,302 from $2,267,890. Cash on hand increased substantially to $2,887,874 as of September 30, 2025, up from $1,038,952 at December 31, 2024, primarily due to $6,469,002 in proceeds from equity financings, including a $5.05 million private placement and a $1.5 million registered direct offering in July 2025. The company also purchased $2,637,360 in digital assets during the nine-month period. Lixte regained compliance with Nasdaq's $2.5 million stockholders' equity requirement on July 15, 2025, but remains under a Panel Monitor until July 15, 2026. The company continues to face substantial doubt about its ability to continue as a going concern, despite estimating sufficient cash for the next 12 months, as it has no recurring revenue and relies on equity financing.

Why It Matters

Lixte's continued reliance on equity financing and lack of revenue generation signals high risk for investors, despite recent capital raises totaling over $6.5 million. The significant increase in cash to $2,887,874 provides a temporary buffer, but the company's 'going concern' warning persists, indicating long-term viability challenges. For employees and customers, the focus on advancing LB-100 and potential acquisitions could bring stability or further uncertainty. In the competitive biopharmaceutical market, Lixte's ability to secure additional capital and successfully develop its lead anti-cancer compound LB-100 will be critical to its survival and ability to compete with larger, more established players.

Risk Assessment

Risk Level: high — The company reported a net loss of $3,465,626 for the nine months ended September 30, 2025, and has no recurring source of revenue, indicating a fundamental lack of sustainable operations. Furthermore, the filing explicitly states, "These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the consolidated financial statements are issued."

Analyst Insight

Investors should exercise extreme caution and consider LIXT a highly speculative investment. While recent equity financings have boosted cash to $2,887,874, the company's ongoing 'going concern' warning and lack of revenue mean future dilution is highly probable. Monitor progress on LB-100 clinical trials and any announced acquisitions closely, but be aware of the significant capital requirements and inherent risks.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$3.47M

eps

-$0.92

gross Margin

N/A

cash Position

$2.89M

revenue Growth

N/A

Key Numbers

• $3.47M — Net Loss (Increased from $2.97M for the nine months ended September 30, 2024, indicating growing operational losses.)
• $2.89M — Cash (Increased from $1.04M at December 31, 2024, primarily due to equity financings.)
• $6.47M — Financing Proceeds (Net cash provided by financing activities for the nine months ended September 30, 2025, crucial for funding operations.)
• $202,801 — R&D Costs (Decreased significantly from $691,402 for the nine months ended September 30, 2024.)
• $3.08M — G&A Costs (Increased from $2.27M for the nine months ended September 30, 2024, indicating rising administrative expenses.)
• $2.64M — Digital Asset Purchases (New investment in digital assets during the nine months ended September 30, 2025.)
• $4.91M — Total Stockholders' Equity (Increased from $827,219 at December 31, 2024, helping regain Nasdaq compliance.)
• $0.92 — Net Loss Per Share (Decreased from $1.32 for the nine months ended September 30, 2024, due to increased share count.)
• 5,704,200 — Common Shares Outstanding (Increased from 2,249,290 at December 31, 2024, reflecting significant dilution.)
• $510,000 — Contractual Commitments (Remaining financial commitments for clinical trials through December 31, 2027.)

Key Players & Entities

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — registrant
• Nasdaq Capital Market (regulator) — exchange for common stock and public warrants
• LB-100 (product) — lead anti-cancer clinical compound
• $3,465,626 (dollar_amount) — net loss for nine months ended September 30, 2025
• $2,887,874 (dollar_amount) — cash balance as of September 30, 2025
• $6,469,002 (dollar_amount) — net cash provided by financing activities for nine months ended September 30, 2025
• $5.05 million (dollar_amount) — proceeds from July 2025 private placement
• $1.5 million (dollar_amount) — proceeds from July 2025 registered direct offering
• $2,637,360 (dollar_amount) — purchase of digital assets for nine months ended September 30, 2025
• July 15, 2026 (date) — end of Nasdaq Panel Monitor period

FAQ

Risk Factors

• Substantial Doubt About Going Concern [high — financial]: The company has not generated revenue and relies on equity financing to fund operations, leading to substantial doubt about its ability to continue as a going concern. Despite recent equity financings totaling $6.47 million, the lack of recurring revenue and ongoing operational losses ($3.47 million net loss for nine months ended Sep 30, 2025) present a significant financial risk.
• Nasdaq Panel Monitor Status [medium — regulatory]: Lixte Biotechnology Holdings, Inc. regained compliance with Nasdaq's $2.5 million stockholders' equity requirement on July 15, 2025, but remains under a Panel Monitor until July 15, 2026. Any future deficiency in stockholders' equity could trigger a hearing and potential delisting.
• Dependence on Equity Financing [high — operational]: The company's operations are entirely dependent on periodic infusions of equity capital. The success of its business model hinges on its ability to secure future funding, which is not guaranteed and can be subject to market conditions and investor sentiment.
• Clinical Stage Development Risks [high — operational]: As a clinical-stage biopharmaceutical company, Lixte faces inherent risks in drug development, including the high failure rate of drug candidates, lengthy development timelines, and significant costs associated with clinical trials. The company has $510,000 in contractual commitments for clinical trials through December 31, 2027.
• Significant Increase in G&A Costs [medium — financial]: General and administrative costs increased to $3.08 million for the nine months ended September 30, 2025, from $2.27 million in the prior year period. This rise in overhead expenses, without corresponding revenue, further strains the company's financial resources.
• Investment in Digital Assets [medium — financial]: The company purchased $2.64 million in digital assets during the nine-month period. The volatility and regulatory uncertainty surrounding digital assets introduce an additional layer of financial risk and potential for impairment.

Industry Context

Lixte Biotechnology Holdings, Inc. operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on oncology. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like Lixte aim to develop novel cancer therapies by targeting specific biological pathways, such as Protein Phosphatase 2A (PP2A).

Regulatory Implications

Lixte's primary regulatory concern is maintaining its listing on the Nasdaq Capital Market. While it has regained compliance with the minimum stockholders' equity requirement, it remains under a Panel Monitor until July 15, 2026. Any future non-compliance could lead to delisting, severely impacting liquidity and investor confidence.

What Investors Should Do

1. Monitor future financing activities closely.
2. Evaluate the progress of LB-100 and other pipeline developments.
3. Assess the risk associated with the significant investment in digital assets.
4. Consider the implications of the Nasdaq Panel Monitor status.

Key Dates

• 2025-07-15: Regained compliance with Nasdaq's $2.5 million stockholders' equity requirement. — Avoided potential delisting from Nasdaq, providing continued trading for the company's securities.
• 2025-07-08: Completed a $1.5 million registered direct offering. — Provided crucial capital to fund operations and research and development activities.
• 2025-07-02: Closed a $5.05 million private placement. — Significantly boosted the company's cash position, essential for its going concern status and ongoing development.
• 2025-04-03: Nasdaq Hearings Panel granted a further extension through July 3, 2025, to regain compliance. — Provided additional time to secure necessary financing and meet Nasdaq's equity requirements.
• 2024-10-03: Submitted a compliance plan to Nasdaq outlining proposed equity financings. — Demonstrated a proactive approach to addressing Nasdaq's minimum stockholders' equity requirement.
• 2024-08-19: Received notification from Nasdaq of noncompliance with the minimum $2.5 million stockholders' equity requirement. — Triggered a compliance process and potential risk of delisting if not addressed.

Glossary

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The company faces substantial doubt about its ability to continue as a going concern due to its lack of revenue and reliance on financing.)

Stockholders' Equity

The residual interest in the assets of an entity after deducting all its liabilities. It represents the net worth of the company. (Lixte's stockholders' equity increased significantly, allowing it to regain compliance with Nasdaq's listing requirements.)

Panel Monitor

A condition imposed by Nasdaq after a company has been non-compliant with listing rules, requiring oversight for a specified period. (Lixte is subject to a Panel Monitor until July 15, 2026, meaning any future equity deficiency could lead to a hearing.)

Registered Direct Offering

A type of public offering where a company sells newly issued securities directly to a small group of institutional investors. (Lixte raised $1.5 million through this type of offering to fund its operations.)

Private Placement

A sale of securities to a select group of investors, typically institutional or accredited investors, rather than through a public offering. (Lixte raised $5.05 million through a private placement, a key source of its recent capital infusion.)

Protein Phosphatase 2A (PP2A)

An enzyme involved in various cellular processes, including cell growth and division. Inhibitors are being explored as cancer therapies. (Lixte's product pipeline focuses on inhibitors of PP2A for cancer drug development.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Lixte Biotechnology Holdings, Inc. reported a net loss of $3.47 million, an increase from $2.97 million in the prior year period, with no revenue generated in either period. Research and development costs decreased significantly to $202,801 from $691,402, while general and administrative costs rose to $3.08 million from $2.27 million. The company's cash position improved substantially to $2.89 million from $1.04 million at year-end 2024, driven by $6.47 million in equity financing proceeds. Total stockholders' equity also saw a substantial increase to $4.91 million, aiding Nasdaq compliance, though the company remains under a Panel Monitor.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The Nasdaq Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 2033KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-q_001.jpg (GRAPHIC) — 100KB
• form10-q_002.jpg (GRAPHIC) — 101KB
• 0001493152-25-021941.txt ( ) — 10031KB
• lixt-20250930.xsd (EX-101.SCH) — 57KB
• lixt-20250930_cal.xml (EX-101.CAL) — 40KB
• lixt-20250930_def.xml (EX-101.DEF) — 316KB
• lixt-20250930_lab.xml (EX-101.LAB) — 497KB
• lixt-20250930_pre.xml (EX-101.PRE) — 394KB
• form10-q_htm.xml (XML) — 1738KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets – September 30, 2025 (Unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations (Unaudited) – Three Months and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) – Three Months and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements (Unaudited) – Three Months and Nine Months Ended September 30, 2025 and 2024 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 45

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 69

Controls and Procedures

Item 4. Controls and Procedures 69

- OTHER INFORMATION

PART II - OTHER INFORMATION 70

Legal Proceedings

Item 1. Legal Proceedings 70

Risk Factors

Item 1A. Risk Factors 70

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 70

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 70

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 70

Other Information

Item 5. Other Information 70

Exhibits

Item 6. Exhibits 71

SIGNATURES

SIGNATURES 72 2 PART I - FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS LIXTE BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash $ 2,887,874 $ 1,038,952 Advances on research and development contract services — — Prepaid insurance 29,490 20,898 Other prepaid expenses 61,839 85,653 Digital assets 2,454,473 — Total current assets 5,433,676 1,145,503 Total assets $ 5,433,676 $ 1,145,503 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses, including $ 112,033 and $ 27,500 to related parties at September 30, 2025 and December 31, 2024, respectively $ 235,900 $ 83,206 Research and development contract liabilities 235,155 235,078 Series B Convertible Preferred Stock 8% cumulative dividend payable 50,367 — Total current liabilities 521,422 318,284 Commitments and contingencies - Stockholders' equity: Preferred Stock, $ 0.0001 par value; authorized – 10,000,000 shares Series A Convertible Preferred Stock, $ 10.00 per share stated value issued and outstanding – 350,000 shares, convertible into 72,917 shares of common stock — 3,500,000 Series B Convertible Preferred Stock, $ 0.7146 per share stated value issued and outstanding – 3,573,130 shares, convertible into 3,573,130 shares of common stock 2,553,359 Preferred stock, value 2,553,359 Common stock, $ 0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 5,704,200 and 2,249,290 shares at September 30, 2025 and December 31, 2024 570 225 Additional paid-in capital 57,891,644 49,394,687 Accumulated deficit ( 55,533,319 ) ( 52,067,693 ) Total stockholders' equity 4,912,254 827,219 Total liabilities and stockholders' equity $ 5,433,676 $ 1,145,503 See accompanying notes to condensed consolidated financial statements.

Business

Business The Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company's corporate office is located in Boca Raton, Florida. The Company's product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100. The Company's activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its operating requirements. Nasdaq Compliance The Company's common stock and public warrants are traded on the Nasdaq Capital Market under the symbols "LIXT" and "LIXTW", respectively. On June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance with the $ 1.00 minimum closing bid price requirement of the Nasdaq Stock Market LLC ("Nasdaq"). On August 19, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff notifying the Company of its noncompliance with the minimum $ 2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Rule 5550(b)(1). 9 On October 3, 2024, the Company submitted a compliance plan, outlining proposed equity financings. On October 21, 2024, Nasdaq granted the Company an extension through February

View Full Filing

View this 10-Q filing on SEC EDGAR